Refine by
Atrial Fibrilation Articles & Analysis
70 news found
Asundexian is a once-daily, oral investigational agent and has not been approved by any health authority for use in any country, for any indication. About Atrial Fibrillation AF is one of the most common sustained cardiac rhythm disorders (arrhythmias). ...
ByBayer AG
“Previous trials evaluating NOACs vs VKAs for stroke prevention in non-valvular atrial fibrillation have excluded patients with advanced chronic kidney disease. ...
ByBayer AG
Based on these promising clinical results, the landmark Phase III development program OCEANIC in atrial fibrillation and non-cardioembolic stroke has been started. Nearly 30,000 patients worldwide are involved in this program. ...
ByBayer AG
Rivaroxaban Rivaroxaban, as an antithrombotic drug, is widely used in the treatment and prevention of deep vein thrombosis (DVT) symptoms prior to hip or knee replacement surgery, treatment of venous thromboembolism (VTE) and nonvalvular atrial fibrillation, as well as treatment of DVT and pulmonary embolism (PE). ...
Mintu Turakhia, iRhythm’s chief medical officer and chief scientific officer. “First, screening for atrial fibrillation, based on the mSToPS trial, is cost-effective and can provide high value. ...
The study, titled “Cost-Effectiveness of AF Screening with Two-Week Patch Monitors: The mHealth Screening to Prevent Strokes Study,” evaluated the cost-effectiveness of screening for atrial fibrillation (AFib) with Zio XT. The analysis found that systematic screening for AFib in an at-risk population with the iRhythm Zio XT patch provided high value ...
CDT – MO4131: “Near-Real Time Extended Ambulatory ECG Monitoring in Patients With Syncope Unveils a Spectrum of Arrhythmias and High Incidence of Atrial Fibrillation.” Presenter: Dr. Bobbi L. Hoppe, Cardiac Electrophysiologist, Kittitas Valley Healthcare. 1:45 – 2:45 p.m. ...
Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure for people with atrial fibrillation who need an alternative to blood thinners to protect them from a stroke. ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. ...
Biotricity has previously generated and validated algorithms for the automated detection of ECG abnormalities, including Atrial Fibrillation (AF). Given the strong association of AF with increased risk of blood clot formation and hence, ischemic stroke in CKD patients, Biotricity proposes to combine the detection of this arrhythmia with other stroke risk factors ...
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. ...
ByBayer AG
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology (JACC), Clinical Electrophysiology.1 The study ...
The ZEUS System is the AI algorithm and solution component of the Zio® Watch: a sensor-based wearable for noninvasive, clinical grade, long-term continuous monitoring for atrial fibrillation (AFib). Verily also received FDA 510(k) clearance for the Zio Watch (Study Watch with Irregular Pulse Monitor). ...
A range of topics spanning from continuing to care for patients during a pandemic to screening for asymptomatic atrial fibrillation are available. Evidence illustrating how the Zio service has helped healthcare systems improve cardiac patient care can be found in the case studies section of the CRC. ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention ...
ByBayer AG
The other studies used Zio XT for low-risk patients to screen for atrial fibrillation in patients aged 70 years and older, and Zio AT for high-risk patients to monitor for arrhythmias in patients after transcatheter aortic valve replacement. ...
More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible. The latest bit of proof came in the form of a trio of studies presented at the American College of ...
Peter Spector and based on his groundbreaking work concerning the drivers of Atrial Fibrillation. Dr. Ginor, an Advisor and investor in the Company said, “CoreMap’s inventions have broad potential for biological sensing which in turn may unlock patient specific treatment for the millions of people suffering with persistent AF ...
The study will evaluate the Platform for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF) during standard electrophysiology mapping and ablation procedures while also evaluating the incidence of primary adverse events within seven days post-procedure. Atrial Fibrillation (AF) is the most common ...
Once identified, the same device can then deliver immediate treatment to restore the normal heart rhythm and confirm successful treatment. “Atrial fibrillation can severely impact quality of life for patients, and physicians are always seeking out the best tools to treat this disorder,” says Dr. ...